If you can't see this message,  view it in your browser

For Students of Emory University Monday, Nov. 29, 2021

DRUG DISCOVERY AT EMORY   FDA to consider authorization of molnupiravir An advisory committee to the U.S. Food and Drug Administration is scheduled to meet tomorrow to discuss Merck’s emergency-use authorization application for molnupiravir, an antiviral pill for COVID-19 that was discovered at Emory. Emory licensed the drug in 2020 to Ridgeback Biotherapeutics, which later partnered with Merck, to advance it through clinical trials. Molnupiravir was approved in the United Kingdom earlier this month to treat at-risk patients with mild-to-moderate COVID-19. It marks another notable chapter in Emory’s drug development efforts, which have advanced lifesaving therapies for more than three decades. ‘The little pill that could’ may prove useful against COVID-19 The oral antiviral molnupiravir was being developed for another purpose when Emory scientist George Painter pivoted to address the COVID-19 crisis. Painter reflects on the years of work behind getting the drug compound from there to here. Video: Molnupiravir vs. COVID-19 An animated video describes how molnupiravir fools the enzymatic machine that copies the SARS-CoV-2’s RNA genome into making errors. How Emory made its mark in worldwide drug discovery Molnupiravir currently occupies center stage. However, Emory researchers can claim a string of successes, including a lifesaving drug for millions of HIV patients. Watch Emory leaders and inventors weigh in. New site chronicles molnupiravir discovery and Emory drug development history Just launched, Drug Discovery at Emory dives deep on molnupiravir and chronicles the longstanding dedication of Emory researchers to improve the lives and health of as many people as possible.

MORE ABOUT MOLNUPIRAVIR   United Kingdom becomes first country to approve Emory-discovered drug for COVID-19 Emory supports Medicines Patent Pool and Merck license agreement for molnupiravir to treat COVID-19 EUA application submitted for COVID-19 antiviral discovered at Emory Drug launched at Emory reduces virus that causes COVID-19 to undetectable levels View more news stories about molnupiravir and drug discovery at Emory

IN THE NEWS   Emory-developed COVID drug seeks FDA approval Nov. 25 |  George Painter and David Perryman |  Atlanta Journal-Constitution How will the COVID pills change the pandemic? Nov. 21 |  Emory University  |  The New Yorker UK authorizes Merck antiviral pill, 1st shown to treat COVID Nov. 4 |  Emory University |  Associated Press How antiviral pill molnupiravir shot ahead in the COVID drug hunt Oct. 8 |  George Painter |  Nature

For more news, visit the emory news center

Useful Links Emory Forward Campus Life Academic Calendars Emory Libraries   Dooley Report About Us Past Issues Subscribe Contact Us

Emory Home  |  Forward to a Friend

Editor: Leigh DeLozier Executive Director of Communications and Editor in Chief: Laura Douglas-Brown Interim Vice President of Communications and Marketing: Cameron Taylor Dooley Report is published by  Communications and Public Affairs Read the Dooley Report Guidelines Copyright 2022 Emory University | All Rights Reserved 201 Dowman Drive, Atlanta, Georgia 30322 USA | 404.727.6123